Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Alicante (7)

2023

  1. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2021

  1. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2010

  1. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

    Haematologica, Vol. 95, Núm. 11, pp. 1913-1920

2009

  1. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152

2008

  1. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

    Blood, Vol. 112, Núm. 9, pp. 3591-3593

2007

  1. Recomendaciones para la prevención, diagnóstico y tratamiento de osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos

    Medicina Oral, Patologia Oral y Cirugia Bucal, Vol. 12, Núm. 4, pp. 279-283